lyophilized powder is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-02-26. Numbers and descriptions here follow the published literature rather than marketing material.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Analytical results depend on the column, gradient, and detector wavelength chosen by the laboratory, so purity values from different sources are not always directly comparable. Water content, counterion form, and residual trifluoroacetate affect both mass and purity calculations. Microbiological and endotoxin testing are separate from chemical purity and are not covered by a standard chromatographic run. Buyers evaluating a material typically request the full method description rather than a single purity figure.
Lyophilized peptide powder is generally stored at minus twenty degrees Celsius or lower and kept away from light and moisture. Under these conditions degradation is slow, and sealed vials remain stable for extended periods. Once dissolved, the material is less stable, particularly in aqueous buffers near neutral pH, where hydrolysis and oxidation proceed faster. Solutions are usually kept cold and used within days to weeks. Repeated freeze-thaw cycles are avoided because they encourage aggregation.
Identity and purity are established using reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and yields a percentage purity. Mass spectrometry, typically with electrospray ionization, confirms the molecular mass against the expected value. Amino acid analysis or peptide mapping provides additional sequence confirmation. These methods are complementary, since chromatography measures how much material is present while mass spectrometry verifies what that material is. A certificate of analysis normally reports both.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Assessed by visual inspection under ordinary laboratory lighting |
| Molecular mass | Approximately 1419 Da | Monoisotopic mass for the fifteen-residue sequence |
| Solubility class | Freely soluble in water | Stock solutions commonly prepared in water or aqueous buffer |
| Typical storage temperature | -20 °C or below, desiccated | Lyophilized powder; repeated freeze-thaw cycles are usually avoided |
| Common analytical method | Reversed-phase HPLC with UV detection | Frequently paired with mass spectrometry to confirm identity |
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated sequences and other synthesis by-products. Mass spectrometry, typically electrospray ionization coupled to liquid chromatography, confirms the expected mass and helps detect modifications. Amino acid analysis can verify composition when residue-level confirmation is needed. Because common impurities differ from the target by only one or two residues, chromatographic resolution often matters more than a single headline purity percentage. Impurity profiles are most informative when compared against a validated reference standard.
Lyophilized material is generally reported as stable for extended periods when kept cold, dry, and protected from light. In solution, the main degradation routes for a peptide of this type are hydrolysis of peptide bonds and aggregation. The sequence contains no cysteine, so disulfide-driven oxidation is not a primary concern, though methionine and tryptophan are also absent. Stability depends on pH, buffer composition, and concentration, with acidic conditions often reported as more favorable than neutral or alkaline ones. Repeated freeze-thaw cycles can promote aggregation, and how fast degradation proceeds at room temperature in specific formulations remains an open question.
Handling practice centers on limiting moisture, heat, and mechanical stress. Powder is typically allowed to reach room temperature before opening so that condensation does not form on the contents, and solutions are prepared with sterile or low-particulate water. Peptides can adsorb to certain plastics and membrane filters, so container and filter material is sometimes specified to reduce losses at low concentrations. Working aliquots are usually frozen separately rather than sampled repeatedly from one stock. Recording lot number, preparation date, and storage conditions supports later comparison between experiments.
The drills continued the following day and were closely monitored by the militaries of both Australia and New Zealand. The New Zealand Government allocates NZ$200 million of funding for the City Rail Link to removing level crossings in order to ease traffic congestion in Auckland. Andrew Bayly resigns as Minister of Commerce and Consumer Affairs after he "placed a hand" on a staff member's upper arm on 18 February, in what Bayly acknowledges as "overbearing" behavior. 22 February: Police investigate five suspected overnight church arson attempts in Masterton. Chinese warships conduct a second live firing exercise in the Tasman Sea. Prime Minister Luxon confirms that Australian and New Zealand naval forces including HMNZS Te Kaha are monitoring the Chinese vessels. 23 February: LGBT supporters gather in Auckland's Albert Park to protest against Destiny Church's disruption of Pride events on 15 February. The New Zealand Police confirm they are investigating graffiti at the former location of Auckland's Kadimah School, which was discovered on 6 February. 24 February – The Police confirmed they have seized 76 gang patches and filed 337 charges for alleged insignia breaches under the Gangs Act 2024. 25 February: Immigration Minister Erica Stanford announces the Government will ease residency rules to recruit more primary school teachers from overseas. Executive director Helen Potiki and legal counsels Nick Whittington and Kristy McDonald KC resign from the second phase of the Royal Commission of Inquiry into COVID-19 Lessons Learned.
=== Food additive === Silica gel, also referred to as silicon dioxide or synthetic amorphous silica (SAS), is listed by the FDA in the United States as generally recognized as safe (GRAS), meaning it can be added to food products without needing approval. Silica is allowed to be added to food in the US at up to 2% as permitted under 21 CFR 172.480. In the EU, it can be in up to 5% concentrations. In 2018, a re-evaluation by the EFSA Panel on Food Additives and Nutrient Sources added to Food found no indications of toxicity even at the highest estimates of exposure level. Listed uses include: anticaking agent, defoaming agent, stabilizer, adsorbent, carrier, conditioning agent, chill proofing agent, filter aid, emulsifying agent, viscosity control agent, and anti-settling agent. Silica can be found commonly in foods including baked goods, spices and herbs, dairy products, cocoa products, and more.
== Future == The expansion of the genetic code is still in its infancy. Current methodology uses only one non-standard amino acid at the time, whereas ideally multiple could be used. In fact, the group of Jason Chin has recently broken the record for a genetically recoded E. coli strain that can simultaneously incorporate up to 4 unnatural amino acids. Moreover, there has been development in software that allows combination of orthogonal ribosomes and unnatural tRNA/RS pairs in order to improve protein yield and fidelity.
{\displaystyle {\begin{aligned}F_{1}(h)&={\frac {1}{\sqrt {2\pi }}}\exp \left(-{\frac {1}{2}}h^{2}\right)-{\frac {1}{2}}h\,\operatorname {erfc} \left({\frac {h}{\sqrt {2}}}\right)\\F_{\frac {3}{2}}(h)&={\frac {1}{4{\sqrt {\pi }}}}\exp \left(-{\frac {h^{2}}{4}}\right){\sqrt {h}}\left(\left(h^{2}+1\right)K_{\frac {1}{4}}\left({\frac {h^{2}}{4}}\right)-h^{2}K_{\frac {3}{4}}\left({\frac {h^{2}}{4}}\right)\right)\end{aligned}}}
The unaltered proteins were then treated with recombinant FGE from Mycobacterium tuberculosis in vitro in which the aldehyde group was successfully installed at the glycosylation site of Fc (Fig. 3A). Next, the introduction of N-acetylglucoseamine (GlcNAc) to the aldehyde tagged proteins via oxime formation was carried out through the treatment with aminooxy GlcNAc (AO-GlcNAc) (Fig. 3B). The conjugation was confirmed by liquid chromatography-electrospray ionisation-mass spectrometry (LC-ESI-MS) and lectin blot with the GlcNAc-binding wheat germ agglutinin attached to AlexaFluor 647. Having successfully introduced GlcNAc, the monomer was extended with a glycan structure containing GlcNAc, mannose (Man) and galactose (Gal) (Fig. 3C). A mutant endoglycosidase EndoS (EndoS-D233Q) was utilised as it is highly specific for IgG Fc N-linked GlcNAc residues and does not elongate Asn-GlcNAc sites on other proteins or on denatured IgGs. Product formation was again monitored by LC-ESI-MS and lectin blot probing, with the sialic acid-binding sambucus nigra agglutinin attached to fluorescein isothiocyanate. A successful chemical glycosylation of the Fc IgG fragment was achieved which resembles the natural occurring glycosylation pattern. The study discussed above focused on the IgG antibody, however, the application of the aldehyde tag for glycan conjugation could potentially be extended to other proteins.
Sources: en.wikipedia.org
== Awards and honours == 2011 American Chemical Society Cincinnati Chemist of the Year 2015 American Microchemical Society Benedetti Pichler Award 2016 Power List of Top 50 Women Analytical Scientists 2016 Fellow of the Royal Society of Chemistry 2021 The Chromatography Forum of the Delaware Valley Stephen Dal Nogare Award
== After 1945 == After the Second World War, the BRSD was re-founded. The group in the Soviet occupation zone disintegrated after 1946. The organization in West Germany was marginialized because of the Cold War, but was able to revitalize itself after 1968. Today, the BRSD is a member of the Attac network, of Oikocredit, Kairos Europa, and the International League of Religious Socialists.
== Background == The tuberous breast deformity was first described by Rees and Aston in 1976 following which a method of classifying the severity was developed. The surgical classifications refer to which areas of the breast are affected and is divided into three grades; mainly in the inferomedial quadrant (Grade I); in the two inferior quadrants (Grade II); or affecting the whole breast (Grade III). This condition is also known as constricted breasts, tubular breasts, or herniated areolar complexes.
Instead of the original plan of breaking her out of the box, Murphy ended up following Will's truck and from there witnessed Will burying Joan alive. Shortly after Will leaves, Murphy digs up Joan's grave and pulled her to safety. Joan's fingerprints were also found in Murphy's home shortly after Murphy was murdered by Derek Channing. In order to protect Vera and Grace from Joan, Jake decides to kill her at the hospital. As she continues to dream, Joan's mind battles between the evil Joan Ferguson personality and the vulnerable, weak side of Joan which now takes on the separate Kath Maxwell identity, ultimately burying Ferguson and putting her away for good. As she suddenly awakes, Jake is startled and runs off. Fearing that they will be charged with attempted murder, Vera, Will, and Jake are called to the hospital to find Joan, having no memory of them, believing now that she is, in fact, Kath Maxwell. Following her recovery, Joan is returned to Wentworth under orders from the Minister. However, not everyone is convinced of her new “Kath Maxwell” persona. New General Manager, Ann Reynolds blackmails former Top Dog, Lou Kelly into protecting Joan from the other prisoners in exchange for Lou's transgender boyfriend, Reb receiving HRT medication. She later comes face-to-face with Allie, who is now Top Dog, who makes a failed attempt in forcing Joan to face up to her past crimes.
Sources: en.wikipedia.org
In recent years, the clinical understanding of the FDA's "black box" warning has evolved to focus on the balance between medication risks and the risks of untreated depression. While the 2004 and 2006 warnings regarding increased suicidal ideation in children and young adults (under 25) remain, long-term data published through 2024 suggests that these warnings may have led to an unintended decline in depression treatment, which some studies correlate with an increase in suicide deaths among adolescents. Statistical meta-analyses updated in 2022 confirm that while the risk of suicidal thoughts in youth on antidepressants like fluoxetine is approximately twice that of a placebo (4% vs 2%), there remains no statistically significant increase in completed suicides across dozens of pediatric trials. Furthermore, recent data continues to show a protective effect in older populations; for adults aged 65 and older, antidepressant use is associated with a statistically significant decrease in suicidality. Regarding specific treatments, research published between 2021 and 2023 reinforces that fluoxetine is most effective and carries the lowest risk of adverse behavioral events when paired with psychotherapy. A 2022 meta-analysis found that combination therapy (medication plus CBT) resulted in a lower incidence of suicidal events compared to fluoxetine alone.
== Adverse effects == The most common adverse reactions are located at the injection site, which occurred in 43 to 45% of people in studies (as compared to 38% under placebo). Hypersensitivity reactions occurred in fewer than 1% of patients.
As of July 2024, lisdexamfetamine is the only pharmacotherapy approved by the US Food and Drug Administration (FDA) and the Therapeutic Goods Administration for BED. Evidence indicates that its effectiveness in treating BED may be partially due to a psychopathological overlap with attention deficit hyperactivity disorder, a cognitive-control disorder that also benefits from treatment with lisdexamfetamine. Medical reviews of randomized controlled trials have established that lisdexamfetamine, administered at doses between 50 and 70 mg, is safe and effective for treating BED. These reviews consistently report fewer weekly binge eating episodes. Furthermore, a meta-analytic systematic review included a 12-month study showing the medication was effective for a long period of time. Two reviews have found lisdexamfetamine to be superior to placebo in several secondary outcomes, including persistent binge eating cessation and reductions in obsessive-compulsive binge eating symptoms, body weight, and triglycerides. Lisdexamfetamine is a pharmacologically inert prodrug that confers its therapeutic effects for BED after conversion to its active metabolite, dextroamphetamine, which acts in the central nervous system. Dextroamphetamine increases the availability of dopamine and norepinephrine in the prefrontal cortex, which makes major decision-making for the body. Lisdexamfetamine, like all pharmaceutical amphetamines, possesses direct appetite suppressant effects, which may be therapeutically beneficial for BED and its associated comorbidities.
Sources: en.wikipedia.org
It is a synthetic peptide built from fifteen amino acids, with a mass of roughly 1419 daltons. The sequence is reported to match a fragment of a protein present in human gastric juice. It is not a naturally circulating hormone.
It is normally supplied as a lyophilized powder in a sealed vial. The powder dissolves readily in water, and stock solutions are typically prepared shortly before use. Cold storage is standard laboratory practice.
The letters are generally read as shorthand for body protection compound. That label comes from the original research context rather than from formal nomenclature. No standardized nonproprietary name exists for the peptide.
Bacteriostatic water or sterile saline is commonly used to dissolve the powder. The choice of solvent affects stability and preservation. Aqueous solutions are kept refrigerated and are not intended for long-term storage.